Lux Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.luxbio.com
Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01243983
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00851734
- Locations
- 🇺🇸
Product Investigations, Conshohocken, Pennsylvania, United States
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
- Conditions
- Corneal TransplantationCorneal Graft Rejection
- Interventions
- Other: Placebo
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00447642
- Locations
- 🇺🇸
Wilmer Eye Institute, Cornea Service, Baltimore, Maryland, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Duke University Eye Center, Durham, North Carolina, United States
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT00447187
- Locations
- 🇺🇸
USC Doheny Eye Institute, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸The Eye Center at Union Memorial Hospital, Baltimore, Maryland, United States
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT00404885
- Locations
- 🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany
🇮🇳Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
🇺🇸University of Illinois - Chicago, Chicago, Illinois, United States
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
- Conditions
- Uveitis, PosteriorUveitis, IntermediatePanuveitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT00404742
- Locations
- 🇺🇸
University of Illinois - Chicago, Chicago, Illinois, United States
🇺🇸Midwest Eye Institute, Indianapolis, Indiana, United States
🇺🇸Wilmer Eye Institute, Baltimore, Maryland, United States
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
- Conditions
- Uveitis, PosteriorUveitis, IntermediatePanuveitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT00404612
- Locations
- 🇮🇳
Department of Opthalmology, Sankara Nethralaya, Medical Research Foundation,, Chennai, Tamil Nadu, India
🇮🇳Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, Tamil Nadu, India
🇺🇸Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States